TELETRADER News
5/27, 8:32 AM (Source: TeleTrader)
more TeleTrader news

Sanofi, GSK see COVID vaccine approval in Q4

Sanofi S.A. and GlaxoSmithKline plc announced on Thursday that the beginning of enrollment for Phase 3 clinical efficacy study of their jointly-developed COVID-19 vaccine candidate.

The study will include 35,000 adult participants in the United States, Asia, Africa, and Latin America. In the first stage, vaccine efficacy will be tested against the original D.614 virus strain, initially detected in Wuhan, while "a second stage will evaluate a second formulation targeting the B.1.351," the so-called "South African" variant.

"Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved / authorized in Q4 2021. Manufacturing will begin in the coming weeks to enable rapid access to the vaccine should it be approved," the companies said in the statement.

Breaking the News / MS